Hematologic Oncology

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, compares the 2 available BTK inhibitors for patients with mantle cell lymphoma.

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma.

Francesca Gay, MD, PhD, discusses the FORTE trial comparing carfilzomib plus lenalidomide and dexamethasone versus carfilzomib plus cyclophosphamide and dexamethasone in newly diagnosed patients with multiple myeloma.

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses unanswered questions with chimeric antigen receptor T-cell therapy.

Kendra Sweet, MD, an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center, discusses discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia.

Andrew T. Kuykendall, MD, assistant member, Moffitt Cancer Center, discusses the impact of ruxolitinib (Jakafi) in myeloproliferative neoplasms (MPNs).

Celeste Bello, MD, hematologist/oncologist, Moffitt Cancer Center, discusses investigational biomarkers in follicular lymphoma.

As investigators continue to look for ways to improve outcomes for the growing number of patients with CML, the primary goal has shifted from improving overall survival to helping patients achieve treatment-free remission.

Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses a subgroup analysis of the ECHELON-1 study in Hodgkin lymphoma.

A supplemental new drug application has been submitted to the FDA for a once-weekly dosing option of carfilzomib to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

The European Commission has approved CPX-351 (Vyxeos), a fixed-combination of daunorubicin and cytarabine, for adult patients with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients with Waldenström macroglobulinemia.

Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the treatment landscape of chronic myeloid leukemia.

Stephen M. Ansell, MD, PhD, discusses overcoming immune evasion in lymphoma.

Judith Trotman, MBChB, FRACP, FRCPA, discusses zanubrutinib’s effect on patient quality of life and how the BTK inhibitor can be used to extend survival for younger patients with WM.

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent advances in the treatment of patients with acute lymphoblastic leukemia.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the role of PD-1 blockade in lymphoma.

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses the diagnosis of double-hit lymphoma.

Naveen Pemmaraju, MD, discusses SL-401 and the future of treatment for patients with blastic plasmacytoid dendritic cell neoplasm.